中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン産業
Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022
|発行||China Research and Intelligence||商品コード||584391|
|出版日||ページ情報||英文 40 Pages
|中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン産業 Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022|
|出版日: 2017年11月21日||ページ情報: 英文 40 Pages||
当レポートでは、中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン産業について調査分析し、政府政策、供給状況、ロットリリース状況、需要状況、主要メーカー、競合、市場機会、リスクと課題、市場の見通しについて、体系的な情報を提供しています。
Measles, mumps and rubella are acute respiratory infectious diseases caused by viruses, all of which can be spread through droplets coming from respiratory tracts. Children and teenagers are high risk groups of diseases. Breakout of epidemics among groups will not only result in harms to their health but also have a direct impact on normal teaching orders and even cause social panics.
Measles has the highest incidence rate and mortality rate, posing extremely huge threats to children's health. People infected with measles usually have clinic manifestations like fever, rashes and cold. Although rubella and mumps exhibit slight clinic symptoms and favorable prognosis, mumps sometimes brings about serious complications, such as boys with secondary orchitis and girls with secondary ovaritis, further leading to sterility and infertility when they grow up. If women are infected with measles at the early stage of pregnancy, there is a possibility of abortion and fetal malformation.
CRI analyzes that despite reduced incidence rates of measles, rubella and mumps in China in recent years, there is still a big gap between the actual incidence rate of measles and the targeted incidence rate set by WHO, which is required to be less than 1/ 1 million people.
In 2012, China's incidence rate of measles was recorded the lowest, which was only 4.6/ 1 million people, but this rate has shown an uptrend since 2013. The incidence rates of rubella and mumps demonstrated an overall declining trend between 2012 and 2016.
According to CRI, there have been four mainstream vaccines related to measles, rubella and mumps in China by the end of 2017. (1) Measles live attenuated vaccines: five enterprises hold production permits. (2) Measles-mumps combined live attenuated vaccines: two enterprises hold production permits. (3) Measles-rubella combined live attenuated vaccines: two enterprises hold production permits. (4) Measles-mumps-rubella combined live attenuated vaccine (measles-mumps-rubella vaccine): two enterprises hold production permits. In addition, imported measles-mumps-rubella vaccines produced by Glaxo SmithKline are launched into the Chinese market, namely Priorix. Although several enterprises possess production permits of MMR vaccines in China, a part of them have ceased production.
Research by CRI suggests that the sales volume of MMR vaccines exhibited a fluctuating trend in China between 2013 and 2017. This fluctuation is mainly attributed to factors such as government policies and market demand. In 2016, the sales volume of MMR vaccines exceeded 70 million.
The MMR vaccine is gradually taking up the market shares of other vaccines because of its good effect, preventing three types of infectious diseases.
Since 2008, the domestic MMR vaccine has been included in China's planned immunization, and provided free for children of appropriate ages by the government. This measure has promoted the development of the MMR vaccine industry in China. From a long-term perspective, MMR vaccines are expected to be the mainstream products, which will gradually substitute monovalent and combined vaccines.
CRI predicts a promising prospect of the MMR vaccine market since the loosing birth control policy is projected to contribute to an annual newborn population of 20 million or more in China during 2018 and 2022. It is estimated that the market shares of MMR vaccines will rise from 70% in 2017 to over 90% in 2022.
Readers can obtain the following information or more through this report: